Skip to content

Neuropace, Inc. NPCE Preferred Stock

Preferred Stock at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
$0
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$0
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$0
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$0
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$0

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s preferred stock?
Neuropace, Inc. (NPCE) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.